Modality
Bispecific Ab
MOA
Cl18.2
Target
MET
Pathway
Wnt
WMMelanoma
Development Pipeline
Preclinical
Sep 2021
→ Feb 2025
PreclinicalCurrent
NCT08492474
2,215 pts·WM
2021-09→2025-02·Not yet recruiting
NCT04642942
1,760 pts·WM
2023-09→TBD·Active
3,975 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-061.1y agoInterim· WM
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2025-02-06 · 1.1y ago
WM
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08492474 | Preclinical | WM | Not yet recr... | 2215 | EASI-75 |
| NCT04642942 | Preclinical | WM | Active | 1760 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| RAP-2478 | Rapport Ther | Phase 3 | MET |